NovellusDx presenting a groundbreaking AI framework for VUS determination

NovellusDx team will be attending the AACR 2019 annual meeting and will present a poster titled: “Accurate prediction of the signaling pathway activity elicited by Variants of Uncertain Significance (VUS) and their drug sensitivity using Deep Convolutional Neural Networks on fluorescent microscopy images of cells”.

read more

Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional genomics, today announced the signing of a definitive agreement under which NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to approximately 49% of the equity of Cancer Genetics on a fully diluted basis (with certain adjustments). Cancer Genetics will be the surviving entity and expects to remain listed on the Nasdaq Stock Market.

read more

The Chinese Patent Office grants NovellusDx a patent for: METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS

NovellusDx announced that the Chinese Patent Office granted it a patent for: “Methods and systems for identifying patient-specific driver mutations”. The patent, the first of a large patent family, is fully owned by the company and protects its core technology and shall remain in force for 20 years from the international filing date of the application, i.e. until January 15, 2034.

read more

New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine

The Gene Editing Institute has licensed its innovative gene editing technology to NovellusDx to improve the efficiency and speed of NovellusDx’s cancer diagnostic screening tools. With the use of advanced gene editing technology, NovellusDx will be able to identify the genetic mechanism responsible for both the onset and progression of many types of cancer and determine the most effective cancer therapy. NovellusDx will pay royalties to Christiana Care for ten years for the use of its innovative gene editing technology.

read more